Kenvue Inc. (NYSE:KVUE) Shares Sold by Bridgewater Associates LP

Bridgewater Associates LP trimmed its stake in shares of Kenvue Inc. (NYSE:KVUE) by 65.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 229,541 shares of the company’s stock after selling 439,517 shares during the quarter. Bridgewater Associates LP’s holdings in Kenvue were worth $4,901,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Bard Financial Services Inc. raised its holdings in Kenvue by 5.7% during the third quarter. Bard Financial Services Inc. now owns 106,790 shares of the company’s stock worth $2,470,000 after purchasing an additional 5,750 shares in the last quarter. Boyar Asset Management Inc. raised its stake in shares of Kenvue by 7.2% during the 3rd quarter. Boyar Asset Management Inc. now owns 29,171 shares of the company’s stock worth $675,000 after buying an additional 1,948 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of Kenvue during the 3rd quarter worth approximately $1,057,000. Tidal Investments LLC boosted its stake in shares of Kenvue by 9.9% in the third quarter. Tidal Investments LLC now owns 131,128 shares of the company’s stock valued at $3,033,000 after buying an additional 11,849 shares in the last quarter. Finally, Oddo BHF Asset Management Sas acquired a new position in Kenvue during the third quarter worth $1,570,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

KVUE has been the subject of a number of recent analyst reports. Citigroup raised their target price on Kenvue from $21.00 to $22.00 and gave the company a “neutral” rating in a report on Monday. Canaccord Genuity Group upped their target price on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Redburn Atlantic began coverage on shares of Kenvue in a research report on Thursday, April 10th. They set a “neutral” rating and a $23.50 price target for the company. Evercore ISI initiated coverage on Kenvue in a report on Monday, March 24th. They issued an “in-line” rating and a $25.00 price target on the stock. Finally, UBS Group reduced their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Eight investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $24.42.

Kenvue Price Performance

NYSE:KVUE opened at $23.42 on Friday. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The firm has a market cap of $44.93 billion, a price-to-earnings ratio of 44.19, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. The company’s 50-day moving average is $22.86 and its two-hundred day moving average is $22.40. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Research analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.50%. The ex-dividend date is Wednesday, May 14th. Kenvue’s dividend payout ratio is currently 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.